FINDINGS:
Comparison: 2023-05-22.
Lungs: No focal consolidation or suspicious pulmonary nodules. No pneumothorax.
Mediastinum: Cardiomediastinal contours within normal limits. no mediastinal mass.
Pleura/Pleural spaces: No pleural effusion or pleural thickening.
Great vessels/Aorta: No thoracic aortic aneurysm or dissection. tortuosity.
Liver: No focal hepatic lesions. Normal attenuation.
Spleen: Normal in size and attenuation. No focal splenic lesion.
Pancreas: Normal pancreatic contour and enhancement. No focal mass. pancreas is normal.
Adrenal glands: Adrenal glands are normal without nodules.
Kidneys: No hydronephrosis. No enhancing renal mass.
GI tract/Bowel: 1.6 cm lobulated mass involving the transverse colon with focal wall thickening (hyperenhancing). No obstructive process. No focal bowel wall mass identified. nonspecific fluid levels. no bowel obstruction.
Mesentery/Omentum: No ascites. No omental caking.
Mesenteric vessels (SMA/SMV): SMA/SMV are patent without thrombosis.
Urinary bladder: Unremarkable. no focal bladder wall thickening.
Reproductive organs: No adnexal mass. Uterus/prostate within expected size for age.
Lymph nodes: Enlarged retroperitoneal lymph node, short axis 10 mm. Enlarged inguinal lymph node, short axis 13 mm. No pathologically enlarged lymph nodes by size criteria.
Bones/Osseous structures: No aggressive osseous lesion. No acute fracture. no destructive osseous lesion.

IMPRESSION:
- Colon primary malignancy at transverse colon measuring approximately 16 mm.
- Findings concerning for nodal involvement.
- No definite distant metastases identified.
- RECIST 1.1 Summary:
- Target lesions (n=3; ≤2 per organ rule applied).
  • T1: Primary — 27→16 mm (longest diameter).
  • T2: Lymph node — 16→10 mm (short axis).
  • T3: Lymph node — 22→13 mm (short axis).
- SLD baseline: 65 mm.
- SLD current: 39 mm (-40.0% change).
- New lesions: absent (unequivocal).
- - RECIST 1.1 overall response category: PR.
